Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.69 |
| ▸ | POLB | P06746 | 4/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.44 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.44 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2416849 | 1.00 | MAPT (0.69) | MAPTALDH1A1POLBMAPK1TDP1 | |
| SCHEMBL20089103 | 0.98 | ALDH1A1 (0.72) | MAPTALDH1A1POLBMAPK1TDP1 | |
| SCHEMBL29545794 | 0.86 | MAPT (0.56) | MAPTALDH1A1POLBMAPK1TDP1 | |
| SCHEMBL3568875 | 0.86 | SIRT6 (0.56) | MAPTALDH1A1POLBMAPK1TDP1 | |
| SCHEMBL15971829 | 0.86 | MAPT (0.52) | MAPTALDH1A1POLBMAPK1TDP1 | |
| SCHEMBL29656802 | 0.86 | SIRT6 (0.56) | MAPTALDH1A1POLBMAPK1TDP1 | |
| SCHEMBL939117 | 0.86 | ALDH1A1 (0.54) | MAPTALDH1A1POLBMAPK1TDP1 | |
| SCHEMBL30574858 | 0.86 | ALDH1A1 (0.54) | MAPTALDH1A1POLBMAPK1TDP1 | |
| SCHEMBL29656880 | 0.86 | MAPT (0.52) | MAPTALDH1A1POLBMAPK1TDP1 | |
| SCHEMBL113743 | 0.84 | MAPT (0.50) | MAPTALDH1A1POLBMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080547-B2 | Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-12-20 | — | — | US | disclosed |
| US-20100041651-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES AND TRIAZOLOPYRIMIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-02-18 | — | — | US | disclosed |
| EP-2146990-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES AND TRIAZOLOPYRIMIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008145839-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES AND TRIAZOLOPYRIMIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041651-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES AND TRIAZOLOPYRIMIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | FLT3, GLP1R, GLS | MAPT 2893/4885ALDH1A1 358/4885POLB 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.